Skip to Main Content

Paper Details

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Clin Cancer Res
34
2022
Author NameAffiliation
Daniel J DeAngeloDana-Farber Cancer Institute
Neeltje SteeghsNetherlands Cancer Institute
Stephane FerrettiNovartis Institutes for BioMedical Research
  • 1 - 3

Datasets

Release 1.2